| ID | 1082 |
| Name of the vaccine | Infanrix hexa |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Babies and toddlers |
| Description of the vaccine | Diphtheria, tetanus, pertussis (acellular, component), hepatitis B, poliomyelitis (inactivated) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed). |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2000 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | Between 95 and 100%. |
| Vaccine formulation | Powder and suspension |
| Dosage | Two or three injections with at least 2 or 1 month gap. |
| Mechanism of action | Make antibodies. |
| Route of administration | Intramuscular |
| Indications | 6-in-1 vaccine. |
| Export | Marketing Authorisation Holder- GlaxoSmithKline UK Limited |
| Approval | European Medicines Agency |
| Adjuvant | NA |
| Repurposing | For Diphtheria, pertussis, hepatitis B, poliomyelitis and Haemophilus influenza type b. |
| Side effects of vaccine | Sleepiness, loss of appetite, high temperature, swelling, pain, redness, unusual crying, feeling irritable, diarrhoea, vomiting, feeling nervous. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01353703 |
| Reference | https://www.medicines.org.uk/emc/files/pil.2586.pdf |
| Other name | NA |
| Additional Links | https://www.drugs.com/uk/infanrix-hexa.html
|